ELVElevance Health, Inc.

NYSE elevancehealth.com


$ 534.81 $ -3.94 (-0.73 %)    

Friday, 14-Jun-2024 15:59:49 EDT
QQQ $ 479.30 $ 2.47 (0.52 %)
DIA $ 386.46 $ -0.42 (-0.11 %)
SPY $ 542.65 $ 0.33 (0.06 %)
TLT $ 94.67 $ 0.79 (0.84 %)
GLD $ 215.76 $ 2.76 (1.3 %)
$ 534.81
$ 535.20
$ 0.00 x 0
$ 0.00 x 0
$ 531.83 - $ 535.89
$ 406.82 - $ 549.99
584,312
na
124.3B
$ 1.02
$ 19.91
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-18-2024 03-31-2024 10-Q
2 02-21-2024 12-31-2023 10-K
3 10-18-2023 09-30-2023 10-Q
4 07-19-2023 06-30-2023 10-Q
5 04-19-2023 03-31-2023 10-Q
6 02-15-2023 12-31-2022 10-K
7 10-19-2022 09-30-2022 10-Q
8 07-20-2022 06-30-2022 10-Q
9 04-20-2022 03-31-2022 10-Q
10 02-16-2022 12-31-2021 10-K
11 10-20-2021 09-30-2021 10-Q
12 07-21-2021 06-30-2021 10-Q
13 04-21-2021 03-31-2021 10-Q
14 02-18-2021 12-31-2020 10-K
15 10-28-2020 09-30-2020 10-Q
16 07-29-2020 06-30-2020 10-Q
17 04-29-2020 03-31-2020 10-Q
18 02-19-2020 12-31-2019 10-K
19 10-23-2019 09-30-2019 10-Q
20 07-24-2019 06-30-2019 10-Q
21 04-24-2019 03-31-2019 10-Q
22 02-20-2019 12-31-2018 10-K
23 10-31-2018 09-30-2018 10-Q
24 07-25-2018 06-30-2018 10-Q
25 04-25-2018 03-31-2018 10-Q
26 02-21-2018 12-31-2017 10-K
27 10-25-2017 09-30-2017 10-Q
28 07-26-2017 06-30-2017 10-Q
29 04-26-2017 03-31-2017 10-Q
30 02-22-2017 12-31-2016 10-K
31 11-02-2016 09-30-2016 10-Q
32 07-27-2016 06-30-2016 10-Q
33 04-27-2016 03-31-2016 10-Q
34 02-19-2016 12-31-2015 10-K
35 10-28-2015 09-30-2015 10-Q
36 07-29-2015 06-30-2015 10-Q
37 04-29-2015 03-31-2015 10-Q
38 02-24-2015 12-31-2014 10-K
39 10-29-2014 09-30-2014 10-Q
40 07-30-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 elevance-health-exec-says-medicare-earnings-are-growing-this-year-company-is-making-money-to-be-clear-it-is-not-losing-money-in-medicare

- Goldman Sachs Conf

 elevance-health-exec-medicaid-redeterminations-had-impact-on-mix-of-healthy-and-sick-membership

- Goldman Sachs Conf

 cantor-fitzgerald-reiterates-overweight-on-elevance-health-maintains-600-price-target

Cantor Fitzgerald analyst Sarah James reiterates Elevance Health (NYSE:ELV) with a Overweight and maintains $600 price target.

 stephens--co-reiterates-overweight-on-elevance-health-maintains-615-price-target

Stephens & Co. analyst Scott Fidel reiterates Elevance Health (NYSE:ELV) with a Overweight and maintains $615 price target.

 b-of-a-securities-maintains-buy-on-elevance-health-raises-price-target-to-646

B of A Securities analyst Kevin Fischbeck maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $...

 elevance-health-shares-moving-higher-co-now-presenting-at-bernsteins-40th-annual-strategic-decisions-conference-at-900-am-et

Elevance Health (NYSE:ELV) announced today that senior management is scheduled to present at Bernstein's 40th Annual Strate...

 jp-morgan-maintains-overweight-on-elevance-health-raises-price-target-to-631

JP Morgan analyst Lisa Gill maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $628 to ...

 baird-initiates-coverage-on-elevance-health-with-outperform-rating-announces-price-target-of-649

Baird analyst Michael Ha initiates coverage on Elevance Health (NYSE:ELV) with a Outperform rating and announces Price Targe...

 why-unitedhealth-stock-is-sliding-wednesday

UnitedHealth Group Inc. (NYSE: UNH) saw its shares decline significantly following remarks made by CEO Andrew Witty at the Bern...

 mizuho-maintains-buy-on-elevance-health-raises-price-target-to-585

Mizuho analyst Ann Hynes maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $575 to $585.